androgel 50 mg transdermalni gel u vrećici
besins healthcare s.a., rue washington 80, ixelles, belgija - testosteron - transdermalni gel u vrećici - 50 mg - urbroj: jedna vrećica (5 g gela) sadrži 50 mg testosterona
midolam 15 mg/3 ml rastvor za injekciju
licentis doo sarajevo - midazolam - rastvor za injekciju - 15 mg/3 ml - 3 ml rastvora za injekciju sadrži: 15 mg midazolama (5 mg/ml)
dutasterid/tamsulozin accord 0,5 mg/0,4 mg tvrde kapsule
accord healthcare polska sp. z o.o., ul. tasmowa 7, mazowieckie, varšava, poljska - dutasteridum, tamsulosinum - kapsula, tvrda - 0,5 mg + 0,4 mg - urbroj: svaka kapsula sadrži 0,5 mg dutasterida i 0,4 mg tamsulozinklorida (ekvivalentno 0,367 mg tamsulozina)
omnic ocas 0,4 mg tablete s produljenim oslobađanjem
astellas d.o.o., ilica 1, zagreb - tamsulozinklorid - tableta s produljenim oslobađanjem - 0,4 mg - urbroj: jedna tableta s produljenim oslobađanjem sadrži 0,4 mg tamsulozinklorida
duitam 0,5 mg/0,4 mg tvrde kapsule
genericon pharma gesellschaft m.b.h., hafnerstraße 211, graz, austrija - dutasterid tamsulozinklorid - kapsula, tvrda - 0,5 mg + 0,4 mg - urbroj: svaka tvrda kapsula sadrži 0,5 mg dutasterida i 0,4 mg tamsulozinklorida (što odgovara 0,367 mg tamsulozina)
duster duo 0,4 mg/1 kapsula+ 0,5 mg/1 kapsula kapsula, tvrda
pliva d.o.o.sarajevo - dutasterid, tamsulosin - kapsula, tvrda - 0,4 mg/1 kapsula+ 0,5 mg/1 kapsula - jedna kapsula, tvrda sadrži: 0,5 mg dutasterida 0,4 mg tamsulosin hidrohlorida
dupro plus 0,5 mg/0,4 mg tvrde kapsule
zentiva k.s., u kabelovny 130, dolni mecholupy, prag 10, Češka - dutasterid tamsulozinklorid - kapsula, tvrda - 0,5 mg + 0,4 mg - urbroj: jedna tvrda kapsula sadrži 0,5 mg dutasterida i 0,4 mg tamsulozinklorida (što odgovara 0,367 mg tamsulozina)
verion duo 0,5 mg/1 kapsula+ 0,4 mg/1 kapsula kapsula, tvrda
bosnalijek d.d. - dutasterid, tamsulosin - kapsula, tvrda - 0,5 mg/1 kapsula+ 0,4 mg/1 kapsula - 1 kapsula sadrži: 0,5 mg dutasterida i 0,4 mg tamsulozin hidrohlorida (što odgovara 0,367 mg tamsulozina)
yervoy
bristol-myers squibb pharma eeig - Ипилимумаб - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - antineoplastična sredstva - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4. yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 i 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.
yervoy 5 mg/1 ml koncentrat za otopinu za infuziju
amicus pharma d.o.o. - ipilimumab - koncentrat za otopinu za infuziju - 5 mg/1 ml - 1 ml koncentrata za otopinu za infuziju sadrži 5 mg ipilimumaba (1 bočica sa 10 ml koncentrata sadrži 50 mg ipilimumaba)